Uncategorized
Eye care market plays substantial role in Valeant’s plans for 2016
The eye care market is expected to comprise 10% of Valeant Pharmaceuticals International’s business in 2016, Howard Schiller, the company’s then interim CEO, reported at the 2016 J.P. Morgan Healthcare Conference, with overall U.S. revenues expected to total $12.5 billion to $12.7 billion.“In U.S. ophthalmology, since we bought B+L, we’ve taken our contact lens market share from 6% to almost 10%. In a tough cataract surgery market, we gained share against tough competition. Once we get the glaucoma approval later this year, we’ll have another engine for growth,” Schiller said, (Read more...)